Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.00% is 100% below its 5-year average of 17.16%, near the low end of its 5-year range (0.00%–856.40%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 326.15%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
326.15%
DEBT TO ASSETS RATIO AVG 3Y
219.71%
DEBT TO ASSETS RATIO AVG 5Y
17.16%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Aspire Biopharma Holdings, Inc.
Market Cap
$1.02M
Debt to Assets Ratio
0.00%
TTM Avg
326.15%
3Y Avg
219.71%
5Y Avg
17.16%
Market Cap
$1.11M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$888387.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$885939.00
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$878396.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$787624.00
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.36M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | $1.02M | 0.00% | 326.15% | 219.71% | 17.16% |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | 0.11% | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | 0.00% | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | 0.01% | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | 0.00% | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $787624.00 | 0.01% | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $707297.00 | 0.38% | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | 0.01% | N/A | N/A | N/A |
| PMGC Holdings Inc. (ELAB)vs › | $1.49M | 0.38% | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.54M | 0.06% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
7.99
Interest Coverage
-2.3x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 21.06% |
| 2025-12-31 | 394.41% |
| 2025-09-30 | 358.90% |
| 2025-06-30 | 856.40% |
| 2025-03-31 | 344.14% |
| 2024-12-31 | 856.03% |
| 2024-09-30 | 6.55% |
| 2024-06-30 | 8.80% |
| 2024-03-31 | 9.90% |
| 2023-12-31 | 0.06% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 81.37% |
| 2021-09-30 | 94.23% |
| 2021-06-30 | 52.62% |
| 2021-03-31 | 51.75% |
